FDA issued EUA for the Janssen COVID-19 vaccine manufactured at Emergent BioSolutions facility in Baltimore
On Jun. 11, 2021, The FDA issued an emergency use authorization (EUA) for the Janssen COVID-19 vaccine, two batches of vaccine drug substance manufactured at the Emergent BioSolutions facility in Baltimore.
Before making this decision, the FDA conducted a thorough review of facility records and the results of quality testing performed by the manufacturer.
Tags:
Source: U.S. Food and Drug Administration
Credit:
